Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.

NCT02868580 is registered in ClinicalTrials.gov with Neuroscience Trials Australia as lead sponsor.

NCT NCT02868580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02868580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.
Lead sponsor
Neuroscience Trials Australia
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2016
Completion date
December 31, 2018
Enrollment
43 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis